Clinical Trial Update: Study to Assess the Safety of Escalating Doses of AT9283, in Patients With Leukemias [Phase 1, Phase 2]

View source ↗

Summary

An early-phase study of escalating doses of AT9283 for various leukemias has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Chronic Myeloid Leukemia
• Myelodysplastic Syndromes
• Myelofibrosis

Drugs mentioned

• AT9283 (AT9283)

Snippet

Sponsor: Astex Pharmaceuticals, Inc. | Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia | Phase 1, Phase 2 | Status: TERMINATED